Condition
Recurrent Leukemia
Total Trials
4
Recruiting
1
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Active Not Recruiting2
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04090619Active Not Recruiting
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
NCT04874480Phase 1Active Not RecruitingPrimary
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
NCT01790152Recruiting
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
NCT04597086Not ApplicableCompleted
Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
Showing all 4 trials